How convergent evolution is creating new COVID-19 waves

NewsGuard 100/100 Score

In a recent study published on the bioRxiv* preprint server, an international team of researchers presented a detailed account of the unique evolutionary trajectory of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), with a focus on its unprecedented scale in the third year of the pandemic.

Study: Convergent evolution in SARS-CoV-2 Spike creates a variant soup that causes new COVID-19 waves. Image Credit: rosedesigns / Shutterstock.com

Study: Convergent evolution in SARS-CoV-2 Spike creates a variant soup that causes new COVID-19 waves. Image Credit: rosedesigns / Shutterstock.com

This news article was a review of a preliminary scientific report that had not undergone peer-review at the time of publication. Since its initial publication, the scientific report has now been peer reviewed and accepted for publication in a Scientific Journal. Links to the preliminary and peer-reviewed reports are available in the Sources section at the bottom of this article. View Sources

Background

The evolution of SARS-CoV-2 and its scale and trajectory has no precedence in the history of modern virology. While other viruses, such as the influenza virus, have mutated due to their inherent mutagenicity, massive human intervention has changed the natural course of SARS-CoV-2 evolution.

First, the easing of non-pharmaceutical interventions (NPIs), such as lockdowns, with the waning of vaccine- and infection-induced immunity, created conditions conducive to unperturbed SARS-CoV-2 evolution in 2022. Additionally, the widescale use of therapeutics and global vaccination campaigns changed its natural course beyond expectations in 2022. Thus, in 2022, the world experienced large infection waves and a surge in excess COVID-19-related hospitalizations and deaths, similar to 2020. 

Increased SARS-CoV-2 loads in humans, combined with selective pressure due to vaccines and therapeutics targeting the SARS-CoV-2 receptor-binding domain (RBD), have also led to an unprecedented rise in the emergence of new SARS-CoV-2 variants in 2022.

The World Health Organization (WHO) nomenclature system has not designated a new name for any SARS-CoV-2 variant of concern (VOCs) following the emergence of the Omicron variant. However, the alternative nomenclature system, PANGOLIN, has introduced new name(s) for emerging Omicron sublineages.

Intriguingly, all Omicron sublineages that arose in 2022 represent 45% of SARS-CoV-2 mutability. Unfortunately, due to a shortage of funds, global genomic surveillance for SARS-CoV-2 declined by 75% in 2022.

Despite the diverse SARS-CoV-2 strains detected in 2022, these reports may still underestimate SARS-CoV-2 evolution in the ongoing pandemic.

Implications of the convergent SARS-CoV-2 evolution

Between 2020 and 2021, mutations at five amino acid (AA) residues in the SARS-CoV-2 spike (S) protein, including K417, L452, E484, N501, and P681, marked its convergent evolution and gave rise to Alpha, Beta, Gamma, and Delta VOCs.

Omicron and its sublineages have acquired additional mutations at eight AA residues, including R346, N450, N460, F486, F490, K444, S494, and Q493, all of which have increased their viral fitness. These Omicron subvariants have evolved at an accelerated pace to avert the effect of all anti-S monoclonal antibodies (mAbs), including cilgavimab and bebtelovimab.

All Omicron subvariants with higher RBD immune escape scores relative to their parental strains are more fit than their parental strains. Thus, according to the researchers, any human intervention, such as changing the COVID-19 vaccine formulation, that disturb this ongoing phenomenon will likely reset how SARS-CoV-2 mutates.

Another remarkable aspect of this unique SARS-CoV-2 convergent evolution is the advent of this 'variant soup,' which is stratified based on the number of crucial S mutations.

In the first two years of the COVID-19 pandemic, when there were no or minimal selective pressures, SARS-CoV-2 acquired mutations that increased the stability of the S protein. More recently, several Omicron sublineages, such as BA.4.6.3 and BQ.1.1.10, acquired convergent mutations in the N-terminal domain (NTD).

Despite sharing a common ancestor, BQ.1.18 and BQ.1.1.20 independently acquired Y144del, N460K, L452R, R346T, F486V, and R493Q reverse mutations.

Several Omicron sublineages further mutated those mutations that prior variants had recently acquired, in most cases to fine-tune their angiotensin-converting enzyme 2 (ACE2) binding capability. For example, BA.2.3 has an E484A mutation like its parental strain, BA.2; however, this mutation further evolved into 484G in the descending strain, BA.2.3.20, which increased its ACE2 affinity.

Ironically, mAbs, such as Evusheld™, which is used to treat chronically ill immunocompromised (IC) patients, provided an ideal environment for the advent of SARS-CoV-2 mutants. Accordingly, the researchers examined the increased circulation of Omicron sublineages with S: R346X mutations in countries with high vs. low usage of Evusheld™, such as France and the United Kingdom.

The vast number of Omicron sublineages also served as a natural experiment to study substitution mutations that remained elusive due to their combined incompatibility. The researchers found evidence of SARS-CoV-2 convergent evolution acting on genes other than those encoding its S protein. For example, XBB.1 mutated at open reading frame (ORF)8:G8x, whereas many BA.5.2* sublineages mutated at ORF1b: T1050.

Conclusions

Based on the unpredictable nature of SARS-CoV-2 evolution, for which the researchers could not ascertain a set trajectory, they recommend polyclonal passive immunotherapies, as these treatments appear to be more escape-resistant than mAbs. Likewise, they advocated for future investigations into combination therapies for high-risk populations, such as IC patients.

This news article was a review of a preliminary scientific report that had not undergone peer-review at the time of publication. Since its initial publication, the scientific report has now been peer reviewed and accepted for publication in a Scientific Journal. Links to the preliminary and peer-reviewed reports are available in the Sources section at the bottom of this article. View Sources

Journal references:

Article Revisions

  • May 18 2023 - The preprint preliminary research paper that this article was based upon was accepted for publication in a peer-reviewed Scientific Journal. This article was edited accordingly to include a link to the final peer-reviewed paper, now shown in the sources section.
Neha Mathur

Written by

Neha Mathur

Neha is a digital marketing professional based in Gurugram, India. She has a Master’s degree from the University of Rajasthan with a specialization in Biotechnology in 2008. She has experience in pre-clinical research as part of her research project in The Department of Toxicology at the prestigious Central Drug Research Institute (CDRI), Lucknow, India. She also holds a certification in C++ programming.

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Mathur, Neha. (2023, May 18). How convergent evolution is creating new COVID-19 waves. News-Medical. Retrieved on May 18, 2024 from https://www.news-medical.net/news/20221211/How-convergent-evolution-is-creating-new-COVID-19-waves.aspx.

  • MLA

    Mathur, Neha. "How convergent evolution is creating new COVID-19 waves". News-Medical. 18 May 2024. <https://www.news-medical.net/news/20221211/How-convergent-evolution-is-creating-new-COVID-19-waves.aspx>.

  • Chicago

    Mathur, Neha. "How convergent evolution is creating new COVID-19 waves". News-Medical. https://www.news-medical.net/news/20221211/How-convergent-evolution-is-creating-new-COVID-19-waves.aspx. (accessed May 18, 2024).

  • Harvard

    Mathur, Neha. 2023. How convergent evolution is creating new COVID-19 waves. News-Medical, viewed 18 May 2024, https://www.news-medical.net/news/20221211/How-convergent-evolution-is-creating-new-COVID-19-waves.aspx.

Comments

  1. SMJ Mortazavi SMJ Mortazavi Iran says:

    This report states that "while other viruses, such as the influenza virus, have mutated due to their inherent mutagenicity, massive human intervention has changed the natural course of SARS-CoV-2 evolution". It's also great to see that the author has paid much attention to the selective pressure induced by vaccines and treatment methods that target the SARS-CoV-2 receptor-binding domain (RBD) "Increased SARS-CoV-2 loads in humans, combined with selective pressure due to vaccines and therapeutics targeting the SARS-CoV-2 receptor-binding domain (RBD), have also led to an unprecedented rise in the emergence of new SARS-CoV-2 variants in 2022.".

    Our team was among the first to independently warned the public about what we called it "Unintentional Directed Accelerated Evolution of Novel Coronavirus (SARS-CoV-2)".
    https://pubmed.ncbi.nlm.nih.gov/32337192/

    We also discussed how selective pressure-inducing treatments may lead to the emegence of new SARS-CoV-2 variants.
    https://pubmed.ncbi.nlm.nih.gov/33937119/
    https://www.mdpi.com/2673-592X/1/1/3

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Pre-vaccine COVID-19: US study reveals hospitalization rate of 5.7% and fatality rate of 1.7%